Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified
Joachim H Ix*, L Darryl Quarles and Glenn M Chertow
Correspondence *Division of Nephrology, Department of Medicine, Box 0532, HSE 672, University of California, San Francisco, CA 94143-0532, USA
Email jix@medicine.ucsf.edu
In the third article of our series on secondary hyperparathyroidism in renal disease, Joachim Ix and colleagues comment on the recommendations put forth by Matthieu Monge et al. on page 326. Ix et al. contend that the changes to current practice proposed by Monge and colleagues are supported by insufficient evidence and should be revisited only when more data from high-quality trials become available.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Achieving NKF-K/DOQI? bone metabolism and disease treatment goals with cinacalcet HClKidney International Trade News
The role of calcimimetics in chronic kidney diseaseKidney International Original Article
Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney diseaseKidney International Original Article
See all 77 matches for Research